tiprankstipranks
Crispr Therapeutics AG (CRSP)
NASDAQ:CRSP
US Market
CRSP
Crispr Therapeutics AG
RESEARCH TOOLSreports
Want to see CRSP full AI Analyst Report?

Crispr Therapeutics AG (CRSP) Ratios

10,904 Followers

Crispr Therapeutics AG Ratios

CRSP's free cash flow for Q4 2025 was $-67.71. For the 2025 fiscal year, CRSP's free cash flow was decreased by $ and operating cash flow was $-179.13. See a summary of the company’s cash flow.
Ratios
TTM
Dec 25Dec 24Dec 23Dec 22
Liquidity Ratios
Current Ratio
 13.25 13.32 22.07 17.54 15.30
Quick Ratio
 13.25 13.32 22.07 17.54 15.30
Cash Ratio
 2.38 2.38 3.40 3.58 1.75
Solvency Ratio
 -1.64 -1.64 -1.12 -0.39 -1.70
Operating Cash Flow Ratio
 -2.31 -2.31 -1.63 -2.39 -4.09
Short-Term Operating Cash Flow Coverage
 -18.57 -18.57 -8.26 -16.66 -31.29
Net Current Asset Value
$ 1.63B$ 1.64B$ 1.63B$ 1.56B$ 1.49B
Leverage Ratios
Debt-to-Assets Ratio
 0.17 0.17 0.10 0.11 0.11
Debt-to-Equity Ratio
 0.21 0.21 0.12 0.13 0.13
Debt-to-Capital Ratio
 0.17 0.17 0.10 0.11 0.12
Long-Term Debt-to-Capital Ratio
 0.09 0.09 0.00 0.00 0.00
Financial Leverage Ratio
 1.18 1.18 1.16 1.18 1.20
Debt Service Coverage Ratio
 -28.33 -29.74 -26.08 -13.16 -40.95
Interest Coverage Ratio
 0.00 0.00 0.00 0.00 0.00
Debt to Market Cap
 0.04 0.04 <0.01 <0.01 <0.01
Interest Debt Per Share
 4.39 4.39 2.65 3.01 3.14
Net Debt to EBITDA
 -0.08 -0.07 0.17 0.74 -0.05
Profitability Margins
Gross Profit Margin
-6490.28%-6537.01%-215.00%64.80%-25186.70%
EBIT Margin
-15443.90%-16191.40%-1333.05%-60.15%-154394.72%
EBITDA Margin
-14890.34%-15636.44%-1278.02%-54.78%-148850.69%
Operating Profit Margin
-16191.40%-16191.40%-1333.05%-60.15%-154394.72%
Pretax Profit Margin
-16466.24%-16466.24%-1036.19%-40.74%-149197.25%
Net Profit Margin
-16569.77%-16569.77%-1046.43%-41.52%-149122.71%
Continuous Operations Profit Margin
-16569.77%-16569.77%-1046.43%-41.52%-149122.71%
Net Income Per EBT
100.63%100.63%100.99%101.92%99.95%
EBT Per EBIT
101.70%101.70%77.73%67.73%96.63%
Return on Assets (ROA)
-25.67%-25.67%-16.34%-6.89%-28.99%
Return on Equity (ROE)
-31.53%-30.26%-18.96%-8.16%-34.67%
Return on Capital Employed (ROCE)
-26.86%-26.86%-21.66%-10.49%-31.72%
Return on Invested Capital (ROIC)
-26.75%-26.62%-21.49%-10.42%-31.47%
Return on Tangible Assets
-25.67%-25.67%-16.34%-6.89%-28.99%
Earnings Yield
-12.42%-12.33%-11.03%-3.10%-20.57%
Efficiency Ratios
Receivables Turnover
 0.00 0.00 1.40 1.85 0.00
Payables Turnover
 20.77 20.92 7.50 3.41 4.02
Inventory Turnover
 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
 0.00 0.01 0.13 1.21 <0.01
Asset Turnover
 <0.01 <0.01 0.02 0.17 <0.01
Working Capital Turnover Ratio
 <0.01 <0.01 0.02 0.21 <0.01
Cash Conversion Cycle
 -17.57 -17.45 212.02 90.40 -90.80
Days of Sales Outstanding
 0.00 0.00 260.71 197.30 0.00
Days of Inventory Outstanding
 0.00 0.00 0.00 0.00 0.00
Days of Payables Outstanding
 17.57 17.45 48.70 106.90 90.80
Operating Cycle
 0.00 0.00 260.71 197.30 0.00
Cash Flow Ratios
Operating Cash Flow Per Share
 -3.84 -3.84 -1.69 -3.29 -6.38
Free Cash Flow Per Share
 -3.85 -3.85 -1.71 -3.41 -6.85
CapEx Per Share
 0.01 0.01 0.02 0.12 0.48
Free Cash Flow to Operating Cash Flow
 1.00 1.00 1.01 1.04 1.08
Dividend Paid and CapEx Coverage Ratio
 -377.48 -377.48 -75.10 -27.49 -13.33
Capital Expenditure Coverage Ratio
 -377.48 -377.48 -75.10 -27.49 -13.33
Operating Cash Flow Coverage Ratio
 -0.87 -0.87 -0.64 -1.09 -2.03
Operating Cash Flow to Sales Ratio
 -98.29 -98.29 -4.08 -0.70 -1.14K
Free Cash Flow Yield
-6.89%-7.34%-4.36%-5.44%-16.86%
Valuation Ratios
Price-to-Earnings (P/E) Ratio
 -7.54 -8.11 -9.07 -32.28 -4.86
Price-to-Sales (P/S) Ratio
 1.34K 1.34K 94.87 13.40 7.25K
Price-to-Book (P/B) Ratio
 2.28 2.45 1.72 2.63 1.69
Price-to-Free Cash Flow (P/FCF) Ratio
 -13.59 -13.63 -22.95 -18.38 -5.93
Price-to-Operating Cash Flow Ratio
 -12.72 -13.67 -23.26 -19.05 -6.38
Price-to-Earnings Growth (PEG) Ratio
 0.20 -0.17 -0.07 0.42 0.02
Price-to-Fair Value
 2.28 2.45 1.72 2.63 1.69
Enterprise Value Multiple
 -9.07 -8.66 -7.26 -23.72 -4.92
Enterprise Value
 5.06B 4.76B 3.25B 4.81B 3.19B
EV to EBITDA
 -9.68 -8.66 -7.26 -23.72 -4.92
EV to Sales
 1.44K 1.35K 92.74 13.00 7.32K
EV to Free Cash Flow
 -14.62 -13.75 -22.44 -17.82 -5.99
EV to Operating Cash Flow
 -14.66 -13.78 -22.73 -18.47 -6.44
Tangible Book Value Per Share
 21.37 21.37 22.90 23.77 24.12
Shareholders’ Equity Per Share
 21.37 21.37 22.90 23.77 24.12
Tax and Other Ratios
Effective Tax Rate
 >-0.01 >-0.01 >-0.01 -0.02 <0.01
Revenue Per Share
 0.04 0.04 0.41 4.67 <0.01
Net Income Per Share
 -6.47 -6.47 -4.34 -1.94 -8.36
Tax Burden
 1.01 1.01 1.01 1.02 1.00
Interest Burden
 1.07 1.02 0.78 0.68 0.97
Research & Development to Revenue
 78.22 75.59 9.16 1.05 1.06K
SG&A to Revenue
 20.95 20.95 2.09 0.21 235.01
Stock-Based Compensation to Revenue
 20.65 20.65 2.47 0.22 224.65
Income Quality
 0.59 0.59 0.39 1.70 0.76
Currency in USD